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Randall disease is an unusual cause of extraocular motor nerve (VI) palsy. A 35-year-old woman was hospitalized for sicca
syndrome. The physical examination showed general weakness, weight loss, diplopia related to a left VIth nerve palsy, hypertrophy
of the submandibular salivary glands, and peripheral neuropathy. The biological screening revealed renal insuﬃciency, serum
monoclonalkappalightchainimmunoglobulin,urinarymonoclonalkappalightchainimmunoglobulin,albuminuria,andBence-
Jones proteinuria. Bone marrow biopsy revealed medullar plasma cell inﬁltration. Immunoﬁxation associated with electron
microscopy analysis of the salivary glands showed deposits of kappa light chains. Randall disease was diagnosed. The patient
received high-dose melphalan followed by autostem cell transplantation which led to rapid remission. Indeed, at the 2-month
followup assessment, the submandibular salivary gland hypertrophy and renal insuﬃciency had disappeared, and the peripheral
neuropathy, proteinuria, and serum monoclonal light chain had decreased signiﬁcantly. The persistent diplopia was treated with
nerve decompression surgery of the left extraocular motor nerve. Cranial nerve complications of Randall disease deserve to be
recognized.
1.Introduction
Randall disease (RD) is characterized by tissue deposition of
monoclonal immunoglobulin light chains without tinctorial
properties[1].WereportacaseofRDassociatedwithplasma
cell dyscrasia, left VIth nerve palsy, peripheral neuropathy,
kidney disease, and submandibular salivary gland hypertro-
phy.
2.CaseReport
A 35-year-old woman was hospitalized for sicca syndrome
lasting for 6 months. In addition to general weakness
and a 6kg weight loss, the physical examination showed
diplopia related to left VIth nerve palsy as conﬁrmed
by the ophthalmological examination, submandibular sali-
vary gland enlargement, and peripheral neuropathy con-
ﬁrmed by the electromyogram. Biological screening revealed
moderate renal insuﬃciency with creatinine clearance
at 47mL/min/1.73m2, serum monoclonal kappa light
chain immunoglobulin with a level of 175mg/L and a
kappa/lambda ratio of 49, urinary monoclonal kappa light
chain immunoglobulin, and proteinuria at 2g/24 hours
with positive Bence-Jones proteinuria. Bone marrow biopsy
revealed medullar plasma cell inﬁltration representing up
to 20% of medullar cells. However, there were no other
criteria for multiple myeloma. Immunoﬁxation associated
with electron microscopy analysis of the salivary glands2 Case Reports in Medicine
Figure 1: Immunohistologic analysis of submandibular salivary
gland biopsy showing deposits of light chain monoclonal immuno-
globulin in the perivascular space and connective tissues. Deposits
are brick-red after Masson’s Trichrome stain.
showeddepositsofkappalightchainswithoutcharacteristics
of amyloidosic proteins (Figure 1). In light of these abnor-
malities, RD associated with plasma cell dyscrasia, left VIth
nerve palsy, peripheral neuropathy, kidney disease, and sub-
mandibular salivary gland hypertrophy was diagnosed. The
patient received high dose melphalan (HDM) (200mg/m2)
followed by autostem cell transplantation (SCT) (CD
34 × 106/ k g )w h i c hr e s u l t e di nr a p i ds u b t o t a la n dp e r s i s t e n t
remission. Indeed, two months after the treatment, the
submandibular salivary gland hypertrophy had disappeared,
the general state of health and peripheral neuropathy had
improved, renal function had returned to normal with
an increase in creatinine clearance to 91mL/min/1.73m2
and a decrease in proteinuria (<1g/24 hours), the serum
monoclonal light chain level stood at 9.66mg/L, and the
kappa/lambda ratio was 1.97. However, there was still
dysaesthesia of the left hand and left VIth nerve palsy.
The latter was treated with nerve decompression surgery
with disappearance of diplopia one year later. At the 3-year
followup assessment, there was no recurrence, but only a
persistence of slight paresthesia of the left hand.
3. Discussion
Randall disease is a monoclonal immunoglobulin deposi-
tion disease [2]. Monoclonal immunoglobulin deposition
disease is a systemic disorder with immunoglobulin chain
deposition in a variety of organs, leading to various clin-
ical features [3]. Visceral immunoglobulin chain deposits
may be totally asymptomatic and found only at autopsy
[4]. Submandibular salivary glands can be aﬀected by
monoclonal immunoglobulin deposition disease (MIDD).
However, peripheral neuropathy and cranial nerve palsies in
general, and extraocular motor nerve (VI) palsy associated
with diplopia in particular, in the context of RD, are rarely
reported in the literature. In 1998, Grassi et al. reported
the ﬁrst precise morphologic and clinical description of
neuropathy related to RD [5].
The diagnosis of monoclonal immunoglobulin depo-
sition disease must be suspected in front of nephrotic
syndrome, rapidly progressive tubulointerstitial nephritis, or
echocardiographic ﬁndings indicating diastolic dysfunction
and the discovery of a monoclonal immunoglobulin com-
ponent in the serum and/or the urine [4]. The deﬁnitive
diagnosis is obtained by the immunohistologic analysis
of the biopsy of an aﬀected organ, mainly the kidney,
using a panel of immunoglobulin chain-speciﬁc antibodies,
including anti-κ andanti-λlightchainantibodies tostainthe
non-Congophilic deposits [4]. In our paper, the diagnosis
was made by the immunohistologic analysis of the salivary
glands. There is no standard treatment for RD [6, 7]. Recent
publications have emphasized the success of HDM/auto-
SCT [6] which now appears to be the most reliable and
eﬀective treatment of neurological complications of MIDD
in young patients. Indeed, the literature reports the suc-
cessful treatment of AL amyloid polyneuropathy with this
therapy [8]. Novel therapies—thalidomide, bortezomib, and
lenalidomide—used in myeloma have not been suﬃciently
studied in RD [9]. The future prospects for therapy are based
on the pathophysiology of RD and include the blocking
of light chain binding to mesangial receptors, the use of
transforming growth factor beta (TGF-β) antagonists and
inhibitors of light chain-induced signalling pathways [4].
This paper is educational in that it demonstrates the
interest of considering RD in a clinical picture of a
cranial nerve disorder. Further analyses will conﬁrm the
diagnosis, and appropriate therapy can improve the clinical
abnormalities and prevent potentially serious functional
complications. Finally, because of the rarity of this pathology
and the improvement in symptoms obtained with high-dose
melphalan with auto-SCT and nerve decompression surgery
in this young patient, this paper could contribute to the
medical literature which is currently scarce in this disease.
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